These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 22771754)

  • 1. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
    Hervier B; Devilliers H; Stanciu R; Meyer A; Uzunhan Y; Masseau A; Dubucquoi S; Hatron PY; Musset L; Wallaert B; Nunes H; Maisonobe T; Olsson NO; Adoue D; Arlet P; Sibilia J; Guiguet M; Lauque D; Amoura Z; Hachulla E; Hamidou M; Benveniste O
    Autoimmun Rev; 2012 Dec; 12(2):210-7. PubMed ID: 22771754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.
    Marie I; Josse S; Decaux O; Dominique S; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Tiev KP; Vittecoq O; Noel D; Mouthon L; Menard JF; Jouen F
    Autoimmun Rev; 2012 Aug; 11(10):739-45. PubMed ID: 22326685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies.
    Dugar M; Cox S; Limaye V; Blumbergs P; Roberts-Thomson PJ
    Intern Med J; 2011 Sep; 41(9):674-9. PubMed ID: 20059602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome.
    Lega JC; Fabien N; Reynaud Q; Durieu I; Durupt S; Dutertre M; Cordier JF; Cottin V
    Autoimmun Rev; 2014 Sep; 13(9):883-91. PubMed ID: 24704867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification.
    Wu S; Xiao X; Zhang Y; Zhang X; Wang G; Peng Q
    Ann Rheum Dis; 2024 May; 83(6):775-786. PubMed ID: 38395605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
    Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF; Levesque H; Jouen F
    Semin Arthritis Rheum; 2012 Jun; 41(6):890-9. PubMed ID: 22078416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome.
    Marie I; Josse S; Decaux O; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Hachulla E; Vittecoq O; Menard JF; Jouen F; Dominique S
    Eur J Intern Med; 2013 Jul; 24(5):474-9. PubMed ID: 23375620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies.
    Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G
    J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome.
    Martins P; Dourado E; Melo AT; Samões B; Sousa M; Freitas R; Lourenço MH; Fernandes B; Costa E; Parente H; Martins F; Fonseca JE; Cordeiro I; Romão VC; Khmelinskii N; Campanilho-Marques R
    ARP Rheumatol; 2022 Nov; 1(ARP Rheumatology, nº3 2022):190-196. PubMed ID: 35891592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).
    Rojas-Serrano J; Herrera-Bringas D; Mejía M; Rivero H; Mateos-Toledo H; Figueroa JE
    Clin Rheumatol; 2015 Sep; 34(9):1563-9. PubMed ID: 26219488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of anti-histidyl-tRNA synthetase (Jo1) autoantibodies.
    Gomard-Mennesson E; Fabien N; Cordier JF; Ninet J; Tebib J; Rousset H
    Ann N Y Acad Sci; 2007 Aug; 1109():414-20. PubMed ID: 17785330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between anti-PL7 antibodies and increased fibrotic component in patients with antisynthetase syndrome and interstitial lung disease: a cross-sectional study.
    Rivero-Gallegos D; Mejía M; Rocha-González HI; Huerta-Cruz JC; Falfán-Valencia R; Ramos-Martínez E; Mateos-Toledo HN; Castillo-López MF; Rodríguez-Torres YK; Lira-Boussart V; Rojas-Serrano J
    Clin Rheumatol; 2024 Jun; 43(6):1971-1978. PubMed ID: 38642252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC; Cottin V; Fabien N; Thivolet-Béjui F; Cordier JF
    J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and prognostic analysis of idiopathic inflammatory myopathy with positive anti-aminoacyl-tRNA synthetase antibodies: A single center experience.
    Zhang D; Wang H; Zhou X; Yang J; Liu Y; Wang W; Jiang P; Fan B
    Immun Inflamm Dis; 2023 Nov; 11(11):e1085. PubMed ID: 38018600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.
    Pinal-Fernandez I; Casal-Dominguez M; Huapaya JA; Albayda J; Paik JJ; Johnson C; Silhan L; Christopher-Stine L; Mammen AL; Danoff SK
    Rheumatology (Oxford); 2017 Jun; 56(6):999-1007. PubMed ID: 28339994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies.
    Fukamatsu H; Hirai Y; Miyake T; Kaji T; Morizane S; Yokoyama E; Hamada T; Oono T; Koyama Y; Norikane S; Iwatsuki K
    J Dermatol; 2019 Oct; 46(10):886-897. PubMed ID: 31418479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias.
    Watanabe K; Handa T; Tanizawa K; Hosono Y; Taguchi Y; Noma S; Kobashi Y; Kubo T; Aihara K; Chin K; Nagai S; Mimori T; Mishima M
    Respir Med; 2011 Aug; 105(8):1238-47. PubMed ID: 21514811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
    Yoshifuji H; Fujii T; Kobayashi S; Imura Y; Fujita Y; Kawabata D; Usui T; Tanaka M; Nagai S; Umehara H; Mimori T
    Autoimmunity; 2006 May; 39(3):233-41. PubMed ID: 16769657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes.
    Marguerie C; Bunn CC; Beynon HL; Bernstein RM; Hughes JM; So AK; Walport MJ
    Q J Med; 1990 Oct; 77(282):1019-38. PubMed ID: 2267280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.